塔莫西芬用于患有肝细胞癌的成年人
Cho Naing1, Han Ni2, Htar Htar Aung3
1Division of Tropical Health and Medicine, James Cook University, Queensland, Australia.
The Cochrane database of systematic reviews
|August 12, 2024
概括
塔莫西芬对晚期肝癌的死亡率或疾病进展几乎没有影响. 关于他莫西芬的证据
科学领域:
- 肝病学和瘤学 肝病学和瘤学
- 临床试验和证据综合
背景情况:
- 肝细胞癌 (HCC) 是最常见的原发性肝癌.
- 塔莫西芬已被研究用于HCC治疗,但结果不一致.
研究的目的:
- 评估泰莫西芬在患有HCC的成年人中所带来的益处和危害.
- 与没有干预,安慰剂,标准护理或替代治疗进行比较.
主要方法:
- 一个系统的审查和对平行组随机临床试验的元分析.
- 搜索包括主要数据库和试验登记册,截至2024年3月.
- 使用RoB 2评估偏差风险,使用GRADE评估证据确定性.
主要成果:
- 纳入了10项试验,共有1715名参与者,评估了他莫西芬与对照干预措施的对比.
- 塔莫西芬在全因死亡率 (RR 0.99) 和疾病进展 (RR 1.02) 中几乎没有差异.
- 关于严重不良事件,生活质量和非严重不良事件的证据确定性非常低.
结论:
- 由于含有试验的低确定性证据和偏差高风险,他莫西芬在晚期HCC中的作用仍然不确定.
- 需要进一步的研究,特别是对于早期的HCC和组合疗法.
更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
399
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
151
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
151
